pocketful logo
Sanofi India Ltd logo

Sanofi India Ltd

NSE: SANOFI BSE: 500674

₹3965.10

(-1.25%)

Mon, 02 Mar 2026, 03:09 pm

mtf coin illustrationMTF 5x

Sanofi India Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

  • Market Cap

    9127.36

  • Net Profit

    413.30

  • P/B

    16.36

  • Sector P/E

    32.50

  • P/E

    34.06

  • EV/EBITDA

    24.25

  • Debt/Equity (Industry)

    0.09

  • Interest Cover (Industry)

    38.34

  • ROCE (Industry)

    22.21

  • RONW (Industry)

    17.92

  • ROE

    47.13

  • ROCE

    47.95

  • Debt/Equity

    0.02

  • EPS (TTM)

    164.93

  • Dividend Yield

    2.95

  • Book Value

    373.70

  • Interest Cover

    313.73

Analysis

all

thumbs up icon

Pros

  • Dividends per share have increased over the past 10 years.
  • Dividends paid are covered by earnings (1.7x coverage).
  • Sanofi India's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.76%).
  • Sanofi India is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Sanofi India is profitable, therefore cash runway is not a concern.
thumbs up icon

Cons

  • Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
  • Sanofi India's dividend is below the markets top 25% of dividend payers in India (3.08%).
  • High level of physical assets or inventory.
  • Sanofi India is not covered by any analysts.
  • Sanofi India's 1-year earnings growth is less than its 5-year average (4% vs 14%)

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersDEC 2025SEPT 2025JUN 2025MAR 2025DEC 2024
Promoters60.4060.4060.4060.4060.40
FII5.555.575.615.575.63
DII21.3122.2923.0623.0222.93
Public12.7411.7410.9411.0111.04
Government00000

Read More

Technical Analysis

RSI

34.42

MACD

-27.45

50 DMA

4066.53

200 DMA

4962.94

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic4419.404222.104093.604024.803896.303827.503630.20
Fibonacci4222.104146.734100.174024.803949.433902.873827.50
Camarilla4019.364001.273983.194024.803947.013928.933910.84

Pivots Level: Classic

R3

+394.60

4419.40

R2

+197.30

4222.10

R1

+68.80

4093.60

4024.80
4024.80
Pivot Point
LTP: 3859.50

S1

-128.50

3896.30

S2

-197.30

3827.50

S3

-394.60

3630.20

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    4005.40

  • 20-EMA

    4027.02

  • 30-EMA

    4047.75

  • 50-EMA

    4110.71

  • 100-EMA

    4338.52

  • 200-EMA

    4743.66

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
25 Feb 2026board-meetingsAccounts, Quarterly Results, Final Dividend
29 Oct 2025board-meetingsQuarterly Results, Nine Months Results, Interim Dividend
29 Oct 2025dividend₹75.00 Dividend /Share07 Nov 2025
07 Oct 2025dividendInterim Dividend - Rs. - 7507 Nov 2025
25 Mar 2025dividendFinal Dividend - Rs. - 11725 Apr 2025
18 Mar 2025agm
27 Feb 2025dividend₹117.00 Dividend /Share25 Apr 2025
03 Apr 2024dividendFinal Dividend - Rs. - 11703 May 2024
03 Apr 2024agmAnnual General Meeting04 May 2024
23 Feb 2024dividend₹117.00 Dividend /Share03 May 2024

Read More

Peer Comparison

Sanofi India Ltd logo

Sanofi India Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Cipla Ltd logo

Cipla Ltd

Read More

Sanofi India Ltd About

Sanofi India is primarily engaged in the business of manufacturing and trading of drugs and pharmaceuticals. The Company has its own manufacturing facility at Goa. The Company also has various independent contract / third party manufacturers based across the country. The Company sells its products

Industry

Pharmaceuticals - Multinational

Founded

1956

Headquarters

CEO

Aditya Narayan

Employees

Contact

Website icon

Website

http://www.sanofiindialtd.com

Email icon

Email

igrc.sil@sanofi.com

Phone icon

Phone

91-22-28032000

Location icon

Location

Sanofi Hse 117-B Saki Vihar Rd, L&T Business Park Powai, Mumbai, Maharashtra, 400072

Read More

Sanofi India Ltd Company History

YearHistory
2019
  • Sanofi India partnered to reduce diabetes burden on state's health exchequer.
2020
  • Sanofi Pasteur launched VaxLine in India.
  • Sanofi India launched Allergy Free.
  • Sanofi Pasteur launched Tetraxim DTaP booster vaccine for preschoolers in India.
2021
  • Sanofi India announced sale and transfer of Nutraceuticals business to Universal Nutriscience.
  • Sanofi and GSK received approval for Phase 3 trial of COVID-19 vaccine candidate in India.
2023
  • Sanofi received marketing approval for diabetes drug Soliqua in India.
2024
  • Sanofi announced expansion of its Global Capability Centre in Hyderabad.
  • Sanofi received marketing authorization for Beyfortus in India against RSV.
  • Sanofi and Cipla announced exclusive distribution partnership for CNS portfolio in India.

Read More

Deals

Client NameOrder SideQTYAvg PriceDate
VARIEGATE TRADING LTDBuy2298370185431 Mar 2006
UNITED BREWERIES HOLDINGSSell2298370185431 Mar 2006

Read More

Sanofi India Ltd News

Sanofi India Uploads Q4FY25 Investor Call Recording

Sanofi India Limited has uploaded the video recording of its investors/analysts call held on February 26, 2026, discussing Q4FY25 and FY25 financial results on its website.

27 Feb 2026

co actions results

Sanofi India Faces ₹2.37 Crore Tax Demand Order

Sanofi India receives tax order from Tamil Nadu Commercial Tax Officer demanding ₹2.37 crore for FY 2021-22, comprising tax, interest and penalty related to Input Tax Credit claims.

20 Feb 2026

stocks

Sanofi India Schedules Q4 FY25 Results Call Feb 26

Sanofi India Limited announces investor/analysts call on February 26, 2026 at 4:00 PM IST to discuss audited financial results for quarter and year ended December 31, 2025.

19 Feb 2026

stocks

Sanofi India Senior Management Personnel Resigns

Sanofi India Limited announces resignation of Mr. Suresh Babu, Sales & Customer Engagement Head – Diabetes, effective February 12, 2026, to pursue opportunities outside the company.

12 Feb 2026

stocks

Sanofi India Faces ₹1.43 Cr Tax Demand Order

Sanofi India Limited receives tax demand order of ₹1.43 crores from CGST & Central Excise authorities for alleged wrong availment of Input Tax Credit during FY 2018-19 to FY 2022-23.

30 Dec 2025

stocks

Read More

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

pocketful logo

2022-25 Pocketful. All rights reserved, Built with in India

Version -5.76

app image 1app image 2

Stocks:

AllABCDEFGHIJKLMNOPQRSTUVWXYZ

Explore

Calculatorsfooter arrow down icon
Popular Calculatorsfooter arrow down icon
Group Stocksfooter arrow down icon

Others:

NSEBSECDSLNSDLSEBIMCXMSEINCDEXNSE IFSCINDIA INXAccount Closure FormDP Investor CharterBroker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800